03968 Overview

Goldman Sachs Report on Chinese Banks: Goldman Sachs has adjusted its forecasts for Chinese banks, increasing the 2025-27 NIM and fee income slightly while reducing loan growth expectations, leading to a minor decline in pre-provision profit forecasts and an increase in post-tax net profit forecasts.

Target Price Adjustments: The broker maintained target valuation multiples but reduced target prices by an average of 0.3%, indicating a 2% upside potential for Chinese bank stocks listed in Hong Kong.

Stock Recommendations: Goldman Sachs recommended CM BANK for its strong consumer finance recovery and asset quality, while preferring CCB and BANK OF CHINA among large banks due to their completed capital replenishment.

Investment Ratings Overview: The report includes various investment ratings and target prices for major banks, with CM BANK and BANK OF CHINA rated as "Buy," while others like BANKCOMM are rated as "Sell."

CM Bank Financial Results: CM Bank reported preliminary results for 2025, with revenue and net profit at RMB338 billion and RMB150 billion, respectively, indicating a net profit growth of 1% for the year and 3% for Q4.

Goldman Sachs Rating: Goldman Sachs maintained a "Buy" rating for CM Bank, citing its high dividend yield and better DPS growth, while slightly adjusting target prices for its H-/A-shares.

Improving Operating Environment: BOCOM International reports that the operating environment for Chinese banks is improving as market entities recover, with joint-stock banks like CM BANK and CITIC BANK showing stable performance in 2025.

CM BANK Performance: CM BANK is experiencing enhanced risk appetite among mid-to-high-end customers, leading to improvements in core indicators such as overall income and net profit.

CITIC BANK Recovery: CITIC BANK, known for its traditional corporate banking, is seeing a steady recovery in net profit growth.

Investment Focus: The report recommends focusing on structural opportunities in joint-stock banks with stable fundamentals and high dividends as long-term funds continue to flow into the market.

Share Price Performance: CM BANK's share price has recently declined, with A-/H-shares down 5%/4% year-to-date and 8%/6% from three-month highs, as noted in a Goldman Sachs report.

Earnings Outlook: Despite weak 4Q25 results, Goldman Sachs predicts CM BANK's earnings growth for 2026 will be 8%, surpassing the 3% average growth expected for major banks.

Target Prices: Goldman Sachs has set target prices for CM BANK's A-/H-shares at RMB54.68 and $53.41, respectively.

Short Selling Activity: The short selling activity for CM BANK is significant, with $194.95 million in short sales and a ratio of 31.952%.

ICBC Performance: ICBC shares decreased by 1.233%, with a short selling ratio of 16.197% and a neutral rating of 5.8.

Bank of China Update: Bank of China shares fell by 1.071%, with a short selling ratio of 12.697% and a buy rating of 4.94.

CM Bank Insights: CM Bank shares rose by 0.418%, with a significant short selling ratio of 31.262% and a buy rating of 52.96.

Market Trends: Other banks like CCB and ABC also experienced slight declines, while PSBC maintained a buy rating despite a minor drop in share price.

Capital Injection Plans: Chinese authorities are set to inject RMB300 billion into two major state-owned banks, ICBC and ABC, as reported by Goldman Sachs, which did not confirm the rumor but assessed its potential impact.

Impact on Financial Metrics: If the capital injection occurs, it could lead to an estimated 4-7% dilution in EPS and a maximum of 2% dilution in BVPS, while potentially increasing the CET1 ratio by 54 to 61 basis points.

Stock Selection Preferences: Goldman Sachs favors banks with solid balance sheets that have completed capital replenishment, such as CCB, Bank of China, and CM Bank, which are seen as having greater potential for dividend increases.

Current Ratings and Uncertainties: Goldman Sachs maintains a Neutral rating on ICBC and ABC with target prices of HKD5.8 and HKD4.95, respectively, citing uncertainties regarding the capital injection's size, timing, and valuation.